UKHSA IPC for seasonal respiratory infections guideline
Covering the infection prevention and control principles required to prevent transmission of COVID-19 and other respiratory viruses for winter 2021–2022
UKHSA staff with symptoms of a respiratory infection guideline
Covering the management of healthcare staff with symptoms of a respiratory infection, including COVID-19 and positive COVID-19 test results
All Wales COPD guideline
Covering management and prescribing options for people with COPD
GOLD COPD 2022 strategy
A clear summary of GOLD’s 2022 strategy on COPD diagnosis, management, and prevention, including recommendations on COVID-19 and COPD
NICE asthma guideline: chronic asthma management
A practical summary of NICE recommendations on managing chronic asthma in children, young people, and adults, including three management algorithms
NICE asthma guideline: diagnosis and monitoring
A concise summary on the initial assessment, diagnosis, and monitoring of asthma in adults, young people, and children. Includes assessment algorithms
Identifying and managing allergic rhinitis in the asthma population
This management algorithm was developed by a multidisciplinary expert panel: Scadding et al with the support of an educational grant from Mylan.
BTS/SIGN asthma in pregnancy guideline
This summary focuses on recommendations for the management of asthma in pregnant women, including during labour, and recommendations for breastfeeding mothers
Inhaler choice guideline
This management algorithm was developed by a multidisciplinary expert panel: Usmani et al and supported by Chiesi Ltd through the provision of a grant for its production.
BTS/SIGN management of difficult asthma guideline
This brief summary of BTS/SIGN guidance on the assessment and management of difficult asthma includes information on contributory factors and monitoring.
Resource hub
Inhaler standards and competency document
- Previous
- Next
Educational resources
DuoResp® Spiromax® (budesonide/formoterol)
This promotional prescribing summary card has been developed from content provided by Teva UK Limited. Information intended for UK healthcare professionals only.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Teva UK Limited on 0207 540 7117 or medinfo@tevauk.com.
Click here for prescribing information and adverse event reporting
DUOR-GB-00117
Date of preparation: March 2022
Identifying and managing allergic rhinitis in the asthma population
This management algorithm was developed by a multidisciplinary expert panel: Scadding et al with the support of an educational grant from Mylan.
Inhaler choice guideline
This management algorithm was developed by a multidisciplinary expert panel: Usmani et al and supported by Chiesi Ltd through the provision of a grant for its production.